Late outcome of survivors of XXXX .

@entity1164 @entity1 @entity1165 @entity10689 @entity2778 @entity2224 @entity1167 @entity943
This report describes clinical, hemodynamic, and electrophysiologic characteristics of 18 consecutive survivors of @entity1164 due to @entity10689 ( @entity2224 ) between 1986 and 1996. Long-term data in relation to the prescribed therapy are presented. The mean age of the 18 @entity1 was 48 +/- 14 years (median 49). Electrophysiologic studies showed a low inducibility of sustained @entity1165 in 4 @entity1 (22%). Treatment consisted of class III agents, beta blockers, or implantable cardioverter-defibrillators. Two @entity1 were discharged without any therapy. Therapy control was undertaken either by serial drug testing or by the empirical approach. Serious complications of therapy occurred in 2 @entity1 : 1 @entity1 experienced a proarrhythmic effect of antiarrhythmic drug therapy, and the other @entity1 received multiple inadequate defibrillator discharges due to a defect in the transvenous lead. All but 1 @entity1 (94%) remained free of recurrences of @entity1164 during a follow-up time of 45 +/- 29 months (median 41). One @entity1 died 2 weeks after surviving @entity1167 due to intractable @entity2224 while receiving @entity2778 treatment. Therapy guided by electrophysiologic studies did not have any impact on survival. Adverse effects or noncompliance led to discontinuation of drug therapy in 7 @entity1 after a mean period of 31 +/- 30 months. Without any treatment 9 @entity1 remained without recurrences over 45 +/- 33 months. Because of the absence of risk factors for @entity943 recurrence and criteria to select therapy, randomized prospective studies are warranted to assess the optimal therapies in these young, ostensibly healthy @entity1 .
